arrow
T

Tianhong Li

university of california davis
H指数:37
被引数:5,641

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial

在转移性鳞状非小细胞肺癌中使用clotistobart或多西他赛: 随机3期PRESERVE-003试验的1期

2026-03-270
OAAI
Management of Immunotherapy-Related Toxicities, Version 2.2024 Featured Updates to the NCCN Guidelines

免疫治疗相关毒性的管理,2.2024版以NCCN指南的更新为特色

2024-11-010
PRE
Atezolizumab plus stereotactic ablative radiotherapy for medically inoperable patients with early-stage non-small cell lung cancer: a multi-institutional phase I trial
2023-09-027
OAAI
Intravenous immunoglobulin is safe and effective in controlling pre-existing paraneoplastic neuromuscular diseases in cancer patients treated with immune checkpoint inhibitors: two case reports and literature review

静脉注射免疫球蛋白可安全有效地控制接受免疫检查点抑制剂治疗的癌症患者已存在的副肿瘤性神经肌肉疾病: 两例病例报告和文献复习

2023-07-031
OAAI
Management of Immunotherapy-Related Toxicities, Version 1.2022

免疫疗法相关毒性的管理,1.2022版

2022-04-01226
OA